Xenon Pharmaceuticals Inc. 8-K

What Happened Xenon Pharmaceuticals Inc. announced an underwritten public offering that closed on March 12, 2026, raising approximately $707.7 million in net proceeds. The company sold 12,236,843 common shares and pre-funded warrants to purchase 877,194 common shares. The offering was led by J.P. Morgan, Jefferies, TD Securities, Stifel, RBC and William Blair and was conducted under Xenon’s shelf registration on Form S-3ASR.

Key Details

• Public offering price: $57.00 per common share; $56.9999 per pre-funded warrant (public price less $0.0001 exercise price).
• Underwriters’ purchase price from Xenon: $54.0075 per common share; $54.0074 per pre-funded warrant.
• Option exercise: underwriters had a 30‑day option to buy up to 1,710,526 additional shares, which they exercised in full on March 11, 2026.
• Net proceeds: approximately $707.7 million after underwriting discounts, commissions and estimated offering expenses.
• Pre-funded warrant terms: exercise price $0.0001; exercisable until fully exercised; exercises subject to beneficial ownership limits (default 4.99%, adjustable up to 19.99% with notice); cashless exercise permitted; anti-dilution and fundamental-transaction protections included.

Why It Matters This transaction meaningfully strengthens Xenon’s cash position—important for funding clinical programs and operating needs—while increasing the number of shares outstanding and potential future dilution from pre-funded warrant exercises. Investors should note the size of the raise, the exercised overallotment, and the ownership limits and exercise mechanics of the pre-funded warrants, all of which affect share count and voting/ownership dynamics going forward.